Driving Independent Pharmacy Profitability in 2026 with Nicolette Mathey, PharmD, CEO of Atrium24

Episode notes

Send us Fan Mail Schedule an Rx Assessment Peptides, telemedicine, speed-to-market. Independent pharmacies have real profitability levers in 2026 but the winners will be the ones who can move fast and stay compliant. In this episode, Scotty Sykes, CPA, CFP, Bonnie Bond, CPA, MBA, and Austin Murray sit down with Dr. Nicolette Mathey, PharmD, CEO of Atrium24 to unpack what’s changing right now in the compounding and wellness economy. We cover: Why peptides are exploding in demand What to know about BPC-157 and why many think FDA movement could be coming How pharmacies can use telemedicine to keep patients from being captured by big direct-to-consumer platforms Where compounding pharmacies are still thriving Speed to market without reckless risk More About Our Guest: Dr. Nicolette Mathey started her career at Walgreens at age 16 and earned her PharmD from the University of Florida in 2010. After pioneering a successful Bedside Delivery program at BayCare Health Systems, she became the Director of Clinical Services at Pharmacy Development Services. There, she co-developed the Clinical Services Profit Ignitor and played a pivotal role in early data analytics.